Palatin Bets Big on Rare Obesity, Secures Funds for Clinical Push

PRINCETON, NJ – February 17, 2026 – Palatin Technologies has unveiled a sharpened corporate strategy, pivoting hard toward the high-stakes world of rare obesity disorders. Bolstered by a recent $18.2 million financing and a series of strategic deals, the biopharmaceutical company announced today it is advancing two novel drug candidates into clinical trials this year, targeting conditions with no approved treatments and profound patient need.

The company's second-quarter fiscal 2026 results, released today, paint a picture of a firm in transition. While reporting a wider net loss driven by increased research spending, Palatin also detailed a significantly strengthened balance sheet and a clear roadmap for its melanocortin-4 receptor (MC4R) based obesity programs, signaling a deliberate and funded bet on a specialized therapeutic area.

A Focused Assault on Untreatable Diseases

Palatin's pipeline is now squarely aimed at two rare, severe forms of obesity: hypothalamic obesity (HO) and Prader-Willi syndrome (PWS). Both are debilitating conditions rooted in dysfunction of the brain's appetite-regulating pathways, for which there are currently no FDA-approved pharmacological treatments.

Hypothalamic obesity, which affects an estimated 10,000 to 25,000 people in the U.S., often results from damage to the hypothalamus following brain tumor surgery. It triggers uncontrollable hunger and rapid, severe weight gain that is resistant to diet and exercise. Prader-Willi syndrome is a complex genetic disorder affecting up to 22,000 individuals in the U.S., characterized by an insatiable appetite (hyperphagia) that begins in early childhood and leads to life-threatening obesity if not strictly managed.

To address these conditions, Palatin is moving two distinct MC4R agonists forward:
* PL7737, an oral small-molecule drug, is on track for an Investigational New Drug (IND) submission and the start of a Phase 1 clinical trial in the first half of 2026. An oral option could offer significant convenience for patients.
* A next-generation peptide agonist, designed for once-weekly subcutaneous injection, is expected to follow with its own IND submission and Phase 1 trial initiation in the second half of 2026.

"As we progress these programs, we remain focused on delivering differentiated product profiles designed to enhance patient tolerability, including the potential for reduced gastrointestinal side effects, while minimizing off-target effects such as hyperpigmentation," said Carl Spana, Ph.D., President and CEO of Palatin, in a statement. He emphasized that the company's focus on these neuroendocrine disorders "underscores the differentiated nature of our melanocortin platform and our commitment to addressing areas of significant unmet medical need."

Navigating a Competitive Landscape

Palatin is entering a competitive but promising field. The MC4R pathway is a well-validated target for genetic obesity, with Rhythm Pharmaceuticals already marketing its MC4R agonist, setmelanotide (IMCIVREE), for several rare genetic obesity disorders. Rhythm is also in late-stage development for both hypothalamic obesity and Prader-Willi syndrome, giving it a significant head start.

However, Palatin believes its candidates can carve out a meaningful niche. The development of both an oral daily pill and a long-acting weekly injection provides potential advantages in patient preference and administration. Success will hinge on demonstrating a competitive or superior profile, particularly concerning the tolerability issues like nausea that can be associated with this class of drugs. Palatin’s focus on minimizing side effects could be a key differentiator if validated in clinical trials.

Fortifying the Financial Foundation

Developing such specialized drugs is a capital-intensive endeavor. Recognizing this, Palatin has spent the last several months shoring up its finances. In November 2025, the company closed an upsized $18.2 million public offering, providing net proceeds of $16.9 million.

Crucially, the financing also enabled Palatin to regain compliance with the NYSE American's listing standards. The company's stock resumed trading on the exchange under its "PTN" ticker on November 12, 2025, a move that restores market visibility, improves liquidity, and enhances access to capital markets for future needs.

With these funds, Palatin's cash and cash equivalents stood at $14.5 million as of December 31, 2025. The company projects this gives it a cash runway extending beyond March 2027, a critical window to generate key clinical data from its lead obesity programs. The financing also included warrants which, if exercised upon meeting certain clinical milestones, could bring in up to an additional $18.2 million, though this is not guaranteed.

Leveraging Partnerships to Fuel the Core Mission

In parallel with its capital raise, Palatin has streamlined its operations by monetizing non-core assets through strategic partnerships. This strategy provides non-dilutive funding and allows the company to concentrate its resources on the MC4R obesity pipeline.

In January 2026, Palatin sublicensed PL9643, its Phase 3 candidate for dry eye disease, to Altanispac Labs. The deal provided $3.8 million in upfront consideration via debt cancellation and keeps Palatin eligible for future milestones and royalties.

This follows a research collaboration and license agreement with global pharmaceutical giant Boehringer Ingelheim, initiated in August 2025, to develop MCR-targeted therapies for retinal diseases. That partnership has already yielded $2.3 million upfront and a $6.5 million research milestone payment, with the potential for over $300 million in future development, regulatory, and commercial milestones.

"Entering 2026, Palatin is positioned with a strengthened balance sheet, multiple partnerships supported by defined near-term milestones, and a focused and differentiated obesity pipeline that provides a clear path toward sustainable, long-term value creation," Dr. Spana stated.

The company's financial results reflect this strategic investment. Operating expenses for the quarter rose to $7.4 million, up from $2.6 million in the prior year, primarily due to increased research and development costs for the obesity programs. The resulting net loss of $7.3 million, or $(2.86) per share, underscores the cost of advancing its ambitious clinical agenda. Yet for investors and patients alike, this spending represents a calculated and now fully funded push to bring a new class of therapies to those with few, if any, options.